



Market Announcement

8 August 2022

Mesoblast Limited (ASX: MSB) – Suspension from Quotation

Description

The securities of Mesoblast Limited ('MSB') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a capital raising.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

8 August 2022

Ms Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

Dear Melissa,

Request for voluntary suspension for Mesoblast Limited (ASX: MSB)

Pursuant to ASX Listing Rule 17.2, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ: MESO) (the **Company**) requests that ASX grant a voluntary suspension in the trading of the Company's fully paid ordinary shares on the ASX effective prior to the commencement of trading today, 8 August 2022.

As the Company is still undergoing its capital raising, the Company is requesting a voluntary suspension from trading to allow it further time to complete that process, particularly given the global nature of the placement.

For the purposes of ASX Listing Rule 17.2, the Company provides the following information:

- (a) the voluntary suspension is requested to allow the Company further time to complete the capital raising as set out in its trading halt request dated Thursday, 4 August 2022, and to allow the capital raising to take place in an orderly fashion;
- (b) the Company requests that the voluntary suspension remain in place until the earlier of it making an announcement regarding the outcome of the capital raising and the commencement of trading on Wednesday, 10 August 2022;
- (c) the Company anticipates that the voluntary suspension will cease upon it announcing the outcome of the capital raising, which is expected to occur on or before Wednesday, 10 August 2022; and
- (d) the Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the voluntary suspension.

Mesoblast Limited
ABN 68 109 431 870
www.mesoblast.com

Corporate Headquarters
Level 38
55 Collins Street
Melbourne 3000
Victoria Australia
T +61 3 9639 6036
F +61 3 9639 6030

United States Operations
505 Fifth Avenue
Third Floor
New York, NY 10017
USA
T +1 212 880 2060
F +1 212 880 2061

Asia
21 Biopolis Road
#01-22 Nucleos (South Tower)
SINGAPORE 138567
T +65 6570 0635
F +65 6570 0176

Yours sincerely

A handwritten signature in black ink, appearing to be 'PHL', written in a cursive style.

Paul Hughes
Joint Company Secretary
Mesoblast Limited